Physician profile
Alex Liu
NPI 1306335047
$4,133.44
in general payments reported to CMS, 2019-2025
41 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $425 · 2023: $477 · 2024: $764 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,894 · Honoraria: $360 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,894.39 |
| Honoraria | $360.00 |
| Education | $234.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $574.06 | 2023-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $385.45 | 2024-2025 | Lynparza, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $309.94 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Seagen INC. | $280.00 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $222.57 | 2024-2025 | |
| Glaxosmithkline, LLC. | $198.58 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Abbvie INC. | $193.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $179.60 | 2022-2025 | Opdivo |
| Sobi, INC | $127.67 | 2023-2025 | |
| Beone Medicines USA, INC. | $116.73 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $115.49 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.10 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $110.06 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $101.13 | 2024-2025 | |
| Gilead Sciences, INC. | $99.32 | 2022-2025 | Trodelvy |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $94.96 | 2022-2025 | Reblozyl |
| Eisai INC. | $81.48 | 2024-2025 | |
| Incyte Corporation | $68.37 | 2022-2025 | Monjuvi, Pemazyre |
| Genmab U.S., INC. | $63.07 | 2024-2025 | Epkinly, Tivdak |
| Pharmacosmos Therapeutics INC. | $62.23 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $55.45 | 2024-2025 | Fruzaqla |
| Lilly USA, LLC | $50.51 | 2025 | Verzenio, Jaypirca |
| Ipsen Biopharmaceuticals, INC | $49.68 | 2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.02 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $41.84 | 2025 | Clonoseq |
| Tersera Therapeutics LLC | $34.20 | 2024 | Zoladex |
| Array Biopharma INC | $33.92 | 2025 | Lorbrena, Xalkori, Braftovi |
| Genzyme Corporation | $31.42 | 2025 | |
| Taiho Oncology, INC. | $29.44 | 2025 | |
| Puma Biotechnology, INC. | $27.98 | 2025 | |
| Beigene USA, INC. | $27.63 | 2025 | Tevimbra |
| Exelixis INC. | $24.99 | 2025 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $24.83 | 2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $23.20 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.37 | 2025 | |
| Sumitomo Pharma America, INC. | $22.26 | 2025 | Orgovyx |
| Iovance Biotherapeutics, INC. | $21.44 | 2025 | Amtagvi |
| Springworks Therapeutics, INC. | $21.39 | 2025 | Ogsiveo |
| Tempus Ai, INC | $19.61 | 2025 | Xt Cdx |
| Fennec Pharmaceuticals, INC. | $14.32 | 2025 | Fyarro |
| Karyopharm Therapeutics INC. | $13.19 | 2024 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.